Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JNJ-77242113 in adolescents and adults with moderate to severe plaque psoriasis
CTR20233560Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing JNJ-77242113 with Placebo (2 arms). Primary endpoints: Proportion of participants achieving IGA 0 or 1 with at least a 2-grade improvement from baseline at Week 16 and Proportion of participants achieving PASI 90 response at Week 16. Started Dec 2023; status: active.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20233560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233560.